XJPX
8095
Market cap128mUSD
Jul 10, Last price
525.00JPY
1D
1.35%
1Q
9.38%
Jan 2017
134.38%
Name
Astena Holdings Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Astena Holdings Co., Ltd., a Japanese company founded in 1914 and based in Chuo, is engaged in the development and distribution of a wide array of healthcare and chemical products. Its Fine Chemical division specializes in manufacturing and selling active pharmaceutical ingredients (APIs) and vital medical supplies used in treatments for fever reduction, pain relief, inflammation management, and blood vessel constriction. The Medical division focuses on biotechnology-related activities, providing support services for drug development and distributing essential medical equipment. The Health & Beauty Care, and Food segment is responsible for marketing non-prescription medications, raw materials for food and functional food products, and cosmetic ingredients. This division also manages direct-to-consumer sales through online and mail-order platforms, alongside offering contract manufacturing services for cosmetic items. Additionally, Astena Holdings' Industrial Chemicals division produces and supplies specialized chemicals for surface treatment and other industrial applications, serving sectors such as printed circuit boards, electronic devices, general plating processes, and semiconductors. The company, initially known as Iwaki & Co., Ltd., officially adopted the name Astena Holdings Co., Ltd. in June 2021.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑11 | 2024‑11 | 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||